NO20073766L - Smeltede pyrazolderivater og fremgangsmater for behandling av metabolsk-relaterte lidelser derav - Google Patents

Smeltede pyrazolderivater og fremgangsmater for behandling av metabolsk-relaterte lidelser derav

Info

Publication number: NO20073766L
Authority: NO; Norway
Prior art keywords: inhibitors; present; treatment; methods; related disorders
Prior art date: 2004-12-23

Application number

NO20073766A

Other languages

English (en)

Norwegian (no)

Inventor

Graeme Semple

Jae-Kyu Jung

Douglas P Boatman

Thomas O Schrader

Philip J Skinner

Original Assignee

Arena Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-23

Filing date

2007-07-19

Publication date

2007-09-21

2007-07-19 Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc

2007-09-21 Publication of NO20073766L publication Critical patent/NO20073766L/no

Links

238000000034 method Methods 0.000 title abstract 2
150000003217 pyrazoles Chemical class 0.000 title abstract 2
230000002503 metabolic effect Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 abstract 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 abstract 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 abstract 2
239000003623 enhancer Substances 0.000 abstract 2
239000003112 inhibitor Substances 0.000 abstract 2
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 abstract 1
229940077274 Alpha glucosidase inhibitor Drugs 0.000 abstract 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
229940123208 Biguanide Drugs 0.000 abstract 1
208000032928 Dyslipidaemia Diseases 0.000 abstract 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 abstract 1
239000013543 active substance Substances 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
239000003288 aldose reductase inhibitor Substances 0.000 abstract 1
229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 abstract 1
239000003888 alpha glucosidase inhibitor Substances 0.000 abstract 1
150000004283 biguanides Chemical class 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000015556 catabolic process Effects 0.000 abstract 1
208000029078 coronary artery disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 abstract 1
229940125753 fibrate Drugs 0.000 abstract 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
230000003914 insulin secretion Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000000144 pharmacologic effect Effects 0.000 abstract 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 abstract 1
239000002464 receptor antagonist Substances 0.000 abstract 1
229940044551 receptor antagonist Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229940031439 squalene Drugs 0.000 abstract 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20073766A 2004-12-23 2007-07-19 Smeltede pyrazolderivater og fremgangsmater for behandling av metabolsk-relaterte lidelser derav NO20073766L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US63866804P	2004-12-23	2004-12-23
US67652105P	2005-04-29	2005-04-29
PCT/US2005/046599 WO2006069242A2 (fr)	2004-12-23	2005-12-22	Derives de pyrazole condenses, et procedes pour traiter des troubles lies au metabolisme

Publications (1)

Publication Number	Publication Date
NO20073766L true NO20073766L (no)	2007-09-21

Family

ID=36593187

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20073766A NO20073766L (no)	2004-12-23	2007-07-19	Smeltede pyrazolderivater og fremgangsmater for behandling av metabolsk-relaterte lidelser derav

Country Status (24)

Country	Link
US (3)	US7241792B2 (fr)
EP (1)	EP1831178A2 (fr)
JP (1)	JP2008525476A (fr)
KR (1)	KR20070088808A (fr)
CN (2)	CN102321024A (fr)
AR (1)	AR055015A1 (fr)
AU (1)	AU2005319121A1 (fr)
BR (1)	BRPI0519262A2 (fr)
CA (1)	CA2589648A1 (fr)
CU (1)	CU23691B7 (fr)
EA (1)	EA013184B1 (fr)
GE (1)	GEP20105126B (fr)
GT (1)	GT200500379A (fr)
HN (1)	HN2005036256A (fr)
IL (1)	IL183654A0 (fr)
MA (1)	MA29148B1 (fr)
NI (1)	NI200700161A (fr)
NO (1)	NO20073766L (fr)
NZ (1)	NZ555721A (fr)
PA (1)	PA8658301A1 (fr)
PE (1)	PE20060949A1 (fr)
TN (1)	TNSN07236A1 (fr)
TW (1)	TW200635904A (fr)
WO (1)	WO2006069242A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI258478B (en)	2003-10-31	2006-07-21	Arena Pharm Inc	Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US20070093545A1 (en) *	2003-11-21	2007-04-26	Arena Pharmaceuticals, Inc.	4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof
PE20060949A1 (es) *	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina
DK1901731T3 (da)	2005-06-28	2011-06-14	Merck Sharp & Dohme	Niacinreceptoragonister, sammensætninger indeholdende sådanne forbindelser og fremgangsmåder til behandling
BRPI0715160A2 (pt)	2006-08-08	2013-06-11	Sanofi Aventis	imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
DE102007005045B4 (de)	2007-01-26	2008-12-18	Sanofi-Aventis	Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2025674A1 (fr)	2007-08-15	2009-02-18	sanofi-aventis	Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
DE102007054497B3 (de)	2007-11-13	2009-07-23	Sanofi-Aventis Deutschland Gmbh	Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010003624A2 (fr)	2008-07-09	2010-01-14	Sanofi-Aventis	Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation
WO2010068601A1 (fr)	2008-12-08	2010-06-17	Sanofi-Aventis	Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
DK2470552T3 (en)	2009-08-26	2014-02-17	Sanofi Sa	NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
NZ598288A (en)	2009-08-28	2014-02-28	Arena Pharm Inc	Cannabinoid receptor modulators
WO2011107494A1 (fr)	2010-03-03	2011-09-09	Sanofi	Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US8933024B2 (en)	2010-06-18	2015-01-13	Sanofi	Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CA2827057C (fr)	2011-02-25	2022-06-07	Arena Pharmaceuticals, Inc.	Formes cristallines et procedes de preparation d'azacycles condenses (modulateurs des recepteurs des cannabinoides)
WO2012116278A1 (fr) *	2011-02-25	2012-08-30	Arena Pharmaceuticals, Inc.	Modulateurs des récepteurs de cannabinoïdes
US9597340B2 (en)	2011-02-25	2017-03-21	Arena Pharmaceuticals, Inc.	Cannabinoid receptor modulators
ES2929977T3 (es) *	2011-02-25	2022-12-05	Arena Pharm Inc	Moduladores del receptor cannabinoide
WO2012120054A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120056A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683703B1 (fr)	2011-03-08	2015-05-27	Sanofi	Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
EP2766349B1 (fr)	2011-03-08	2016-06-01	Sanofi	Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
EP2683704B1 (fr)	2011-03-08	2014-12-17	Sanofi	Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120058A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120050A1 (fr)	2011-03-08	2012-09-13	Sanofi	Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, médicaments contenant ces composés et leur utilisation
WO2013037390A1 (fr)	2011-09-12	2013-03-21	Sanofi	Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr)	2011-09-27	2013-04-04	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
HK1210825A1 (en)	2012-07-11	2016-05-06	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
KR20200005614A (ko)	2017-05-08	2020-01-15	아레나 파마슈티칼스, 인크.	내장 통증의 치료를 위한 화합물 및 방법
AU2019318209B2 (en)	2018-08-10	2025-09-25	Diapin Therapeutics, Llc	Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3105336A (en) *	1961-05-16	1963-10-01	Package Machinery Co	Converting wrapping machines to wrap different size articles
US4613610A (en) *	1984-06-22	1986-09-23	Sandoz Pharmaceuticals Corp.	Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US5134155A (en) *	1991-08-08	1992-07-28	Ortho Pharmaceutical Corporation	Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
ATE355279T1 (de) *	1998-08-07	2006-03-15	Novartis Vaccines & Diagnostic	Pyrazole als modulatoren des östrogenrezeptors
US6743793B2 (en)	2000-03-09	2004-06-01	Ono Pharmaceutical Co., Ltd.	Indole derivatives, process for preparation of the same and use thereof
US20010047027A1 (en)	2000-04-12	2001-11-29	Marc Labelle	Prostaglandin D2 receptor antagonists
US6410583B1 (en)	2000-07-25	2002-06-25	Merck Frosst Canada & Co.	Cyclopentanoindoles, compositions containing such compounds and methods of treatment
ATE340796T1 (de)	2001-05-23	2006-10-15	Merck Frosst Canada Inc	Dihydropyrrolo(1,2-aöindol- und tetrahydropyrido)1,2-aöindolderivate als prostaglandin rezeptor antagonisten
CN1233648C (zh)	2001-06-27	2005-12-28	尔艾斯特公司	Salen催化剂、催化剂的制备和通过使用催化剂制备手性化合物的方法
KR20040044856A (ko)	2001-09-07	2004-05-31	오노 야꾸힝 고교 가부시키가이샤	인돌 유도체 화합물
DE10148617A1 (de) *	2001-09-25	2003-04-24	Schering Ag	Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AR038136A1 (es)	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
MXPA04009095A (es)	2002-03-19	2004-12-06	Ono Pharmaceutical Co	Compuesto de acido carboxilico y agente farmaceutico que comprende el compuesto como ingrediente activo.
AU2003282679A1 (en)	2002-10-04	2004-05-04	Arena Pharmaceuticals, Inc.	Hydroxypyrazoles for use against metabolic-related disorders
AU2003300014A1 (en) *	2002-10-10	2004-05-04	Arena Pharmaceuticals, Inc.	5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
AR041089A1 (es)	2003-05-15	2005-05-04	Merck & Co Inc	Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
CA2528834A1 (fr) *	2003-06-13	2005-02-10	Arena Pharmaceuticals, Inc.	Derives d'acide 2h-pyrazol-3- carboxylique substitues en 5 utilises comme agonistes du recepteur de l'acide nicotinique rup25 pour le traitement des dyslipidemies et des pathologies apparentees
GB0319124D0 (en)	2003-08-14	2003-09-17	Smithkline Beecham Corp	Chemical compounds
GB0319126D0 (en)	2003-08-14	2003-09-17	Smithkline Beecham Corp	Chemical compounds
TWI258478B (en) *	2003-10-31	2006-07-21	Arena Pharm Inc	Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
HRP20130406T1 (hr)	2004-02-14	2013-06-30	Glaxosmithkline Intellectual Property Development Limited	Medikamenti s aktivnošä†u prema receptoru hm74a
PE20060949A1 (es) *	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina

2005
- 2005-12-15 PE PE2005001472A patent/PE20060949A1/es not_active Application Discontinuation
- 2005-12-20 GT GT200500379A patent/GT200500379A/es unknown
- 2005-12-21 TW TW094145549A patent/TW200635904A/zh unknown
- 2005-12-21 HN HN2005036256A patent/HN2005036256A/es unknown
- 2005-12-21 AR ARP050105438A patent/AR055015A1/es not_active Application Discontinuation
- 2005-12-22 NZ NZ555721A patent/NZ555721A/en not_active IP Right Cessation
- 2005-12-22 GE GEAP200510188A patent/GEP20105126B/en unknown
- 2005-12-22 BR BRPI0519262-5A patent/BRPI0519262A2/pt not_active IP Right Cessation
- 2005-12-22 WO PCT/US2005/046599 patent/WO2006069242A2/fr not_active Ceased
- 2005-12-22 CN CN2011102214069A patent/CN102321024A/zh active Pending
- 2005-12-22 CN CN2011102214054A patent/CN102311378A/zh active Pending
- 2005-12-22 US US11/315,753 patent/US7241792B2/en not_active Expired - Lifetime
- 2005-12-22 KR KR1020077016787A patent/KR20070088808A/ko not_active Ceased
- 2005-12-22 EP EP05857182A patent/EP1831178A2/fr not_active Withdrawn
- 2005-12-22 AU AU2005319121A patent/AU2005319121A1/en not_active Abandoned
- 2005-12-22 EA EA200701361A patent/EA013184B1/ru not_active IP Right Cessation
- 2005-12-22 JP JP2007548472A patent/JP2008525476A/ja not_active Withdrawn
- 2005-12-22 CA CA002589648A patent/CA2589648A1/fr not_active Abandoned
- 2005-12-23 PA PA20058658301A patent/PA8658301A1/es unknown
2006
- 2006-11-17 US US11/601,184 patent/US7612106B2/en not_active Expired - Fee Related
2007
- 2007-06-04 IL IL183654A patent/IL183654A0/en unknown
- 2007-06-20 CU CU20070144A patent/CU23691B7/es not_active IP Right Cessation
- 2007-06-20 TN TNP2007000236A patent/TNSN07236A1/fr unknown
- 2007-06-21 NI NI200700161A patent/NI200700161A/es unknown
- 2007-07-12 MA MA30071A patent/MA29148B1/fr unknown
- 2007-07-19 NO NO20073766A patent/NO20073766L/no not_active Application Discontinuation
2009
- 2009-04-30 US US12/433,704 patent/US20090258892A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2589648A1 (fr)	2006-06-29
WO2006069242A2 (fr)	2006-06-29
CU23691B7 (es)	2011-09-21
GT200500379A (es)	2006-10-25
HN2005036256A (es)	2010-02-08
WO2006069242A3 (fr)	2006-08-31
NI200700161A (es)	2008-04-21
CN102311378A (zh)	2012-01-11
BRPI0519262A2 (pt)	2009-01-06
US20090258892A1 (en)	2009-10-15
AR055015A1 (es)	2007-08-01
US20060205955A1 (en)	2006-09-14
EA013184B1 (ru)	2010-02-26
TW200635904A (en)	2006-10-16
MA29148B1 (fr)	2008-01-02
PA8658301A1 (es)	2006-10-13
US7241792B2 (en)	2007-07-10
EP1831178A2 (fr)	2007-09-12
NZ555721A (en)	2011-02-25
US20070073062A1 (en)	2007-03-29
IL183654A0 (en)	2007-09-20
EA200701361A1 (ru)	2007-12-28
TNSN07236A1 (en)	2008-11-21
US7612106B2 (en)	2009-11-03
CN102321024A (zh)	2012-01-18
KR20070088808A (ko)	2007-08-29
PE20060949A1 (es)	2006-10-11
GEP20105126B (en)	2010-12-10
CU20070144A7 (es)	2010-01-22
AU2005319121A1 (en)	2006-06-29
JP2008525476A (ja)	2008-07-17

Legal Events

Date	Code	Title	Description
2012-07-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
TW200635904A (en)	2006-10-16	Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof
WO2004033431A3 (fr)	2004-07-29	Hydroxypyrazoles et methodes prophylactiques ou de traitement de troubles lies au metabolisme
NO20062509L (no)	2006-06-26	Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav
CA2598536A1 (fr)	2006-08-31	Derives d'oxyindole utilises comme agonistes du recepteur 5ht4
PE20120620A1 (es)	2012-05-27	Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PH12014500937A1 (en)	2015-09-21	5-ht 1a receptor substype agonist
KR102251939B1 (ko)	2021-05-14	Ｃｒｔｈ２ 길항제로서의 피라졸 화합물들
NO20084674L (no)	2009-01-29	1- [ (4-(benzoyl (metyl) amino] -3- (fenyl) butyl] azetidinderivater for behandling av gastrointestinale lidelser
SG158924A1 (en)	2010-02-26	Modulators of chemokine receptor activity, crystalline forms and process
Hu et al.	2022	Orally bioavailable quinoxaline inhibitors of 15-prostaglandin dehydrogenase (15-PGDH) promote tissue repair and regeneration
ATE449092T1 (de)	2009-12-15	Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors
DE60327446D1 (de)	2009-06-10	5-substituierte 2h-pyrazon-3-carbonsäure-derivate als antilipolytische mittel zur behandlung von stoffwechselstörungen, wie z.b. dyslipidemie
WO2005051937A3 (fr)	2005-09-15	Derives d'acide carboxylique 4-oxo-4,5-dihydrofurane-2 et methodes pour traiter des troubles du metabolisme
UA90878C2 (ru)	2010-06-10	Конденсированные производные пиразола и способы лечения с их помощью заболеваний, вызванных нарушением обмена веществ
NO20063562L (no)	2006-11-06	Fusjonerte heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
WO2005118558A3 (fr)	2006-02-09	Composes pyrimidine et leur utilisation
NO20090125L (no)	2009-03-09	Benzimidazolderivater som skal anvendes som antagonist for CB1-reseptor
DOP2005000270A (es)	2006-06-30	Derivados funsionados de pirazol y metodos de tratamiento de trastornos metabolicos co estos.
OA16479A (en)	2015-10-21	Pyrazole compounds as CRTH2 antagonists.
TH83468A (th)	2007-03-08	ยาต้านฤทธิ์ของตัวรับ crf และวิธีการที่เกี่ยวข้องกับเรื่องนี้
FR2926817A1 (fr)	2009-07-31	Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
TH105731A (th)	2011-01-26	ไธอะ(ไดอะ) โซล ที่เป็นแอนทาโกนิสท์ของรีเซพเตอร์โดพามีน 2 ที่แยกตัวออกเร็ว